Announced
Completed
Financials
Tags
precision oncology
Health Care Services
Acquisition
oncology
Domestic
Merger
United States
Public
Friendly
Majority
Single Bidder
Completed
Privatisation
Synopsis
Bristol Myers Squibb, an American multinational pharmaceutical company, completed the acquisition of Turning Point Therapeutics, a clinical-stage precision oncology company, for $4.1bn. "The acquisition of Turning Point Therapeutics further broadens our leading oncology franchise by adding a best-in-class, late-stage precision oncology asset. With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile," Giovanni Caforio, Bristol Myers Squibb Chairman and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.